南昌大学
Nanchang University
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 24 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 24
- 牵头的试验
- 1
- 占中国试验的比例
- 0.2%
- 占全球论文的比例
- 0.7%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma.
- Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
- Serum inflammatory markers as prognostic marker for nasopharyngeal carcinoma with liver metastasis: a multi-center retrospective study.
- Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
- Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective
ClinicalTrials.gov 上的试验6
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
- Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury
- Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 12 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 12
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Entirely Intramural Growth Pattern: A Rare Presentation of Esophageal Squamous Cell Carcinoma and Review of the Literature.
- Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.
- Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer.
- AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.
- TRAF7 inhibits proliferation and migration of esophageal squamous cell carcinoma by ubiquitination-mediated degradation of SOX12.
ClinicalTrials.gov 上的试验6
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 181 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 181
- 牵头的试验
- 1
- 占中国试验的比例
- 0.07%
- 占全球论文的比例
- 0.6%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE.
- Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma.
- Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
- Comparative efficacy and safety of lenvatinib, sintilimab combined interventional therapy vs bevacizumab, sintilimab combined interventional therapy in intermediate and advanced hepatocellular carcinoma: a multicenter re
- Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma.
ClinicalTrials.gov 上的试验6
- Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
- A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 173 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 173
- 牵头的试验
- 1
- 占中国试验的比例
- 0.07%
- 占全球论文的比例
- 0.8%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Adjuvant treatment and molecular mechanism of probiotic compounds in patients with gastric cancer after gastrectomy.
- A Network Information-Based Behavior Change Wheel for Populations at High Risk of Developing Gastric Cancer.
- Clinical significance of the S204 phosphorylation of the Smad3 protein in combination with Ki67 for the metastasis and prognosis of gastric cancer.
- Short- and long-term outcomes of totally robotic versus robotic-assisted total gastrectomy for advanced gastric cancer: a single-center retrospective study.
- Stratified and propensity score matching analysis of the effectiveness of fibrin glue in preventing postoperative bleeding after endoscopic submucosal dissection.
ClinicalTrials.gov 上的试验6
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
视网膜母细胞瘤
Retinoblastoma2021–2025年中国大陆共有 301 篇该病的 PubMed 英文论文,这里牵头了其中 9 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 9
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.8%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- MTHFD2 drives retinoblastoma progression via Notch signaling activation: Implications for targeted pediatric ocular cancer therapy.
- ANRIL regulates retinoblastoma progression via targeting autophagy by miR-328-3p/TSC1/ULK signaling.
- USP14 increases the sensitivity of retinoblastoma to cisplatin by mediating the ferroptosis.
- Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma.
- LncRNA LOXL1-AS1 promotes proliferation and invasion and inhibits apoptosis in retinoblastoma by regulating the MAPK signaling pathway.
脊索瘤
Chordoma2021–2025年中国大陆共有 105 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 60 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 60
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 1.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.
- The Role of Chemotherapy in the Survival Benefits of Patients Aged Older Than 40 Years With Osteosarcoma.
- Reversal of MPPa-PDT Resistance in Osteosarcoma by Targeting ROCK2-Mediated Autophagy.
- GPX8 is transcriptionally regulated by KLF16 and promotes osteosarcoma progression.
- Integrative bioinformatics and experimental validation identify pyrroline-5-carboxylate reductase 1 as a mitochondrial regulator and diagnostic biomarker in osteosarcoma.
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025年中国大陆共有 523 篇该病的 PubMed 英文论文,这里牵头了其中 8 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 8
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Follow-up analysis and research of very low-risk and low-risk gastrointestinal stromal tumors after endoscopic resection.
- Development and validation of a preoperative risk nomogram prediction model for gastric gastrointestinal stromal tumors.
- Comparable long‑term survival outcomes of endoscopic treatment versus surgical treatment for gastrointestinal stromal tumors with a diameter of 5-10 cm.
- Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor.
- Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis.
ClinicalTrials.gov 上的试验4
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
神经母细胞瘤
Neuroblastoma2021–2025年中国大陆共有 1,132 篇该病的 PubMed 英文论文,这里牵头了其中 6 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 6
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Global, regional, and national burden of neuroblastoma and peripheral nervous system tumours in individuals aged over 60 from 1990 to 2021: a trend analysis of global burden of disease study.
- Posterior mediastinal neuroblastoma: A challenging location for treatment and follow-up.
- Anlotinib induces neuronal-like differentiation of neuroblastoma by downregulating CRMP5.
- Model for predicting prognosis and immunotherapy based on CD+8 T cells infiltration in neuroblastoma.
- Exosomal miR-133a-3p Derived from BMSCs Alleviates Cerebral Ischemia-Reperfusion Injury via Targeting DAPK2.
尤文肉瘤
Ewing sarcoma2021–2025年中国大陆共有 163 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 16 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 16
- 牵头的试验
- 2
- 占中国试验的比例
- 0.4%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma.
- The value of myocardial contraction fraction and long-axis strain to predict late gadolinium enhancement in multiple myeloma patients with secondary cardiac amyloidosis.
- A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma.
- Obstructive jaundice caused by pancreatic plasmacytoma secondary to multiple myeloma: A case report and literature review.
- Multiple myeloma with CD138 changed from positive to negative: A case report.
ClinicalTrials.gov 上的试验6
- A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia (B-ALL)2021–2025年中国大陆共有 225 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
- Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.
- Liver and Kidney Tumor Masses as the Initial Presentation of B-Cell Acute Lymphoblastic Leukemia.
ClinicalTrials.gov 上的试验6
- CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
- A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Study of YK012 in B-cell Acute Lymphoblastic Leukemia
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis (HLH)2021–2025年中国大陆共有 399 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- A novel prognosis-prediction model based on coagulation indicators in secondary hemophagocytic lymphohistiocytosis.
- Hemorrhagic fever with renal syndrome presenting as leukemoid reaction and hemophagocytic lymphohistiocytosis.
- Increased levels of serum interleukin-10 are associated with poor outcome in adult hemophagocytic lymphohistiocytosis patients.
- Promising Targeted Therapies for Hemophagocytic Lymphohistiocytosis: A Translational Perspective Based on Immunopathology.
- Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.
非典型溶血性尿毒症综合征
Atypical haemolytic uraemic syndrome2021–2025年中国大陆共有 27 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(11.1%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025年中国大陆共有 64 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder (NMOSD)2021–2025年中国大陆共有 485 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.5%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG-IgG Dual Seropositive: A Case Report.
- Rituximab-induced gut microbiota changes in Chinese neuromyelitis optica spectrum disorders.
- Differentiation between multiple sclerosis and neuromyelitis optic spectrum disorders with multilevel fMRI features: A machine learning analysis.
- Temporal and topological properties of dynamic networks reflect disability in patients with neuromyelitis optica spectrum disorders.
- In patients with mild disability NMOSD: is the alteration in the cortical morphological or functional network topological properties more significant.
ClinicalTrials.gov 上的试验1
重症肌无力
Myasthenia gravis2021–2025年中国大陆共有 499 篇该病的 PubMed 英文论文,这里牵头了其中 4 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 4
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文4
- A cross-sectional study on fear of progression in patients with myasthenia gravis.
- Evaluating the Effectiveness of Large Language Models in Providing Patient Education for Chinese Patients With Ocular Myasthenia Gravis: Mixed Methods Study.
- Comprehensive Analysis of Uric Acid and Myasthenia Gravis: IGF1R as a Protective Factor and Potential Therapeutic Target.
- 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
烟雾病
Moyamoya disease2021–2025年中国大陆共有 356 篇该病的 PubMed 英文论文,这里牵头了其中 9 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 9
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.7%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Association of intravascular enhancement sign on 3D T1- weighted TSE sequences with cerebral perfusion and infarction events in moyamoya disease.
- Network centrality alterations in patients with moyamoya disease after combined revascularization surgery: a resting-state fMRI study.
- Identification of the optimal thresholds for the hypoperfusion intensity ratio in moyamoya disease.
- Machine learning model for predicting stroke recurrence in adult stroke patients with moyamoya disease and factors of stroke recurrence.
- Ischemic patterns and their angiographic risk factors in adult patients with moyamoya disease.
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025年中国大陆共有 989 篇该病的 PubMed 英文论文,这里牵头了其中 6 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 6
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Machine Learning-Driven Discovery of TRIM Genes as Diagnostic Biomarkers for Idiopathic Pulmonary Fibrosis.
- Follicular helper T cells and fibrotic diseases.
- Identification and analysis of extracellular matrix and epithelial-mesenchymal transition-related genes in idiopathic pulmonary fibrosis by bioinformatics analysis and experimental validation.
- Endothelial CD38-induced endothelial-to-mesenchymal transition is a pivotal driver in pulmonary fibrosis.
- USP7 Promotes TGF-β1 Signaling by De-Ubiquitinating Smad2/Smad3 in Pulmonary Fibrosis.
ClinicalTrials.gov 上的试验4
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 8 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 8
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Nocturnal hypoxemia mediates age-related sleep fragmentation in amyotrophic lateral sclerosis: a polysomnographic case-control study.
- Serum creatine kinase dynamics in amyotrophic lateral sclerosis: Predictive role of male sex, limb onset, and intermediate disease duration for stratified monitoring.
- The therapeutic potential of Apigenin in amyotrophic lateral sclerosis through ALDH1A2/Nrf2/ARE signaling.
- Parvalbumin interneurons dysfunction is potentially associated with FαMNs decrease and NRG1-ErbB4 signaling inhibition in spinal cord in amyotrophic lateral sclerosis.
- FUS Mutation Causes Disordered Lipid Metabolism in Skeletal Muscle Associated with ALS.
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025年中国大陆共有 213 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Longitudinal study of multi-parameter quantitative magnetic resonance imaging in Duchenne muscular dystrophy: hyperresponsiveness of gluteus maximus and detection of subclinical disease progression in functionally stable
- Utilization of T1-Mapping for the pelvic and thigh muscles in Duchenne Muscular Dystrophy: a quantitative biomarker for disease involvement and correlation with clinical assessments.
- Identification of hub genes, miRNAs and regulatory factors relevant for Duchenne muscular dystrophy by bioinformatics analysis.
- C-X-C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy.
- Increasing LRP4 diminishes neuromuscular deficits in a mouse model of Duchenne muscular dystrophy.
IgA 肾病
IgA nephropathy2021–2025年中国大陆共有 736 篇该病的 PubMed 英文论文,这里牵头了其中 13 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 13
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.8%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.
- IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristics.
- The efficacy of rituximab in the treatment of IgA vasculitis nephritis.
- Changes in the spectrum of kidney diseases: a survey of 2803 patients from 2010 to 2018 at a single center in southeastern China.
- IgA nephropathy associated with anti-PLA2R antibody positive: a case report.
ClinicalTrials.gov 上的试验6
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- Atrasentan in Patients With IgA Nephropathy
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025年中国大陆共有 300 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验1
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025年中国大陆共有 100 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(7.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。